Login / Signup

Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry.

Jose Miguel Rivera-CaravacaIván J Núñez-GilGregory Yoke Hong LipAitor UribarriMaría C Viana-LlamasAdelina GonzalezAlex F Castro-MejíaBerta Alonso GonzálezEmilio AlfonsoJuan Fortunato García PrietoChiara CavallinoBernardo CorteseGisela FeltesInmaculada Fernández-RozasJaime Signes-CostaJia HuangMarcos García AguadoMartino PepeRodolfo RomeroEnrico CerratoVíctor Manuel Becerra-MuñozSergio Raposeiras RoubinFrancesco SantoroRodrigo BagurLuciano SposatoIbrahim El-BattrawyAlvaro López MasjuanAntonio Fernandez-OrtizVicente EstradaCarlos MacayaFrancisco Marín
Published in: International journal of clinical practice (2022)
Hospitalized COVID-19 patients on prior OAC therapy had a higher risk of mortality and worse clinical outcomes compared to patients without prior OAC therapy, even after adjusting for comorbidities using a PSM. There were no differences in clinical outcomes in patients previously taking VKAs or DOACs. This trial is registered with NCT04334291/EUPAS34399.
Keyphrases
  • sars cov
  • end stage renal disease
  • coronavirus disease
  • newly diagnosed
  • ejection fraction
  • prognostic factors
  • stem cells
  • venous thromboembolism
  • cardiovascular events
  • patient reported outcomes
  • phase iii